Roselló-Lletí Esther, Tarazón Estefanía, Barderas María G, Ortega Ana, Otero Manuel, Molina-Navarro Maria Micaela, Lago Francisca, González-Juanatey Jose Ramón, Salvador Antonio, Portolés Manuel, Rivera Miguel
Cardiocirculatory Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Department of Vascular Physiopathology, Hospital Nacional de Parapléjicos, SESCAM, Toledo, Spain.
PLoS One. 2014 Nov 14;9(11):e112971. doi: 10.1371/journal.pone.0112971. eCollection 2014.
Dilated cardiomyopathy (DCM) is a public health problem with no available curative treatment, and mitochondrial dysfunction plays a critical role in its development. The present study is the first to analyze the mitochondrial proteome in cardiac tissue of patients with DCM to identify potential molecular targets for its therapeutic intervention.
16 left ventricular (LV) samples obtained from explanted human hearts with DCM (n = 8) and control donors (n = 8) were extracted to perform a proteomic approach to investigate the variations in mitochondrial protein expression. The proteome of the samples was analyzed by quantitative differential electrophoresis and Mass Spectrometry. These changes were validated by classical techniques and by novel and precise selected reaction monitoring analysis and RNA sequencing approach increasing the total heart samples up to 25. We found significant alterations in energy metabolism, especially in molecules involved in substrate utilization (ODPA, ETFD, DLDH), energy production (ATPA), other metabolic pathways (AL4A1) and protein synthesis (EFTU), obtaining considerable and specific relationships between the alterations detected in these processes. Importantly, we observed that the antioxidant PRDX3 overexpression is associated with impaired ventricular function. PRDX3 is significantly related to LV end systolic and diastolic diameter (r = 0.73, p value<0.01; r = 0.71, p value<0.01), fractional shortening, and ejection fraction (r = -0.61, p value<0.05; and r = -0.62, p value<0.05, respectively).
This work could be a pivotal study to gain more knowledge on the cellular mechanisms related to the pathophysiology of this disease and may lead to the development of etiology-specific heart failure therapies. We suggest new molecular targets for therapeutic interventions, something that up to now has been lacking.
扩张型心肌病(DCM)是一个尚无有效治愈方法的公共卫生问题,线粒体功能障碍在其发展过程中起关键作用。本研究首次分析DCM患者心脏组织中的线粒体蛋白质组,以确定其治疗干预的潜在分子靶点。
从因DCM而切除的人心脏(n = 8)和对照供体(n = 8)中获取16个左心室(LV)样本,提取后采用蛋白质组学方法研究线粒体蛋白表达的变化。通过定量差异电泳和质谱分析样本的蛋白质组。这些变化通过经典技术以及新颖且精确的选择反应监测分析和RNA测序方法进行验证,将心脏样本总数增加到25个。我们发现能量代谢存在显著改变,尤其是在参与底物利用(ODPA、ETFD、DLDH)、能量产生(ATPA)、其他代谢途径(AL4A1)和蛋白质合成(EFTU)的分子中,在这些过程中检测到的改变之间获得了相当可观且特定的关系。重要的是,我们观察到抗氧化剂PRDX3的过表达与心室功能受损有关。PRDX3与左心室收缩末期和舒张末期直径显著相关(r = 0.73,p值<0.01;r = 0.71,p值<0.01)、缩短分数和射血分数(分别为r = -0.61,p值<0.05;r = -0.62,p值<0.05)。
这项工作可能是一项关键研究,有助于更深入了解与该疾病病理生理学相关的细胞机制,并可能导致病因特异性心力衰竭治疗方法的开发。我们提出了治疗干预的新分子靶点,这是迄今为止一直缺乏的。